2 results
Approved WMOCompleted
To estimate the efficacy of erlotinib administered as a single agent to chemo-naïve NSCLC patients as determined by the non progression rate (NPR) at 8 weeks.
Approved WMORecruiting
Based on the scientific background and knowledge as detailed above this clinical proof-of-mechanism study is performed in order to determine if PET imaging with [18F]DPA-714 has the diagnostic potential to discriminate probable AD patients from…